Join our mission to connect Colombian cultivation with European pharmaceutical markets. Páramo Extracts delivers affordable, high-quality, GACP/GMP pharmaceutical-grade cannabis through a scalable and sustainable model, leveraging Colombia’s climate to reduce costs and carbon footprint.

Investment Opportunity in Páramo Extracts
Through FasterCapital’s EquityPilot Program, Páramo Extracts is raising USD $1.0M – $1.2M.
We are targeting angel investors, venture capital funds, and strategic partners in the life sciences and pharmaceutical-grade cannabis sectors.


Why is Páramo Extracts an attractive investment?
Páramo Extracts combines the advantages of Colombian cultivation (low-cost, high-quality flower) with a European HUB strategy, transforming GACP flower into GMP-compliant pharmaceutical products.
Our model offers:
-
Dual presence in Colombia and Europe, securing both supply and market access.
-
Strong compliance with GACP/GMP standards and regulatory expertise.
-
Cost efficiency, with production costs significantly lower than in North America or Europe.
-
Network of strategic cultivators instead of dependence on a single site, enabling scalability and risk diversification.
This unique structure positions Páramo Extracts as a bridge between Latin American production and European demand, ensuring a consistent supply of pharmaceutical-grade cannabis at competitive margins.

Key Milestones of Páramo Extracts
-
Licenses granted for the cultivation of psychoactive and non-psychoactive cannabis in Colombia.
-
European HUB strategy established for GMP transformation and distribution.
-
Network of strategic GACP cultivators built to ensure scalable and compliant supply.
-
Commercial relationships initiated in Europe (Czech Republic, Switzerland, Germany).
-
Over USD $500,000 invested in licensing, infrastructure, regulatory procedures, and operations.
-
Accepted into FasterCapital’s EquityPilot Program to raise € 1.0M –€ $1.2M.
https://www.fastercapital.com/
Key Message for Investors
Páramo Extracts is building the bridge between Colombia and Europe, transforming low-cost, high-quality cannabis into GACP/GMP pharmaceutical-grade products, ensuring scalability and attractive returns.
